Drug Trial Radar · NCT05128591
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
Last checked: Nov 19, 2026Latest source record: Mar 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Nov 9, 2021
Primary completion
Dec 31, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.
Conditions
- Embolism and Thrombosis
Interventions
Rivaroxaban 18mg Oral TabletDrug
AD-109 (Rivaroxaban 18mg) Oral Tablet
Rivaroxaban 20 MG Oral TabletDrug
AD-1091 (Rivaroxaban 20mg) Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Plasma Concentration (Cmax)Time frame: pre-dose to 34 hours
- Area Under the Curve in time plot (AUCt)Time frame: pre-dose to 34 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H+ Yangji Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.